Conexxence
Authorised
This medicine is authorised for use in the European Union
denosumab
Medicine
Human
Authorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Conexxence is a medicine used to treat the following conditions:
• osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause, Conexxence reduces the risk of fractures in the spine and elsewhere in the body, including the hips;
• bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Conexxence reduces the risk of fractures in the spine;
• bone loss in adults at increased risk of fractures who are treated long term with corticosteroid medicines given by mouth or injection.
Conexxence contains the active substance denosumab and is a biological medicine. It is a ‘biosimilar medicine’; this means that Conexxence is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Conexxence is Prolia. For more information on biosimilar medicines, see here.
Conexxence can only be obtained with a prescription and is available as a solution for injection in prefilled syringes.
It is given once every 6 months as an injection under the skin in the thigh, abdomen (belly) or back of the arm. During treatment with Conexxence, the doctor should ensure that the patient is receiving calcium and vitamin D supplements. Conexxence can be given by someone who has been trained in how to give injections appropriately.
For more information about using Conexxence, see the package leaflet or contact your doctor or pharmacist.
Laboratory studies comparing Conexxence with Prolia have shown that the active substance in Conexxence is highly similar to that in Prolia in terms of structure, purity and biological activity. Studies have also shown that giving Conexxence produces similar levels of the active substance in the body to those seen with Prolia.
In addition, a study involving 553 women with osteoporosis who have been through the menopause compared the effectiveness of Conexxence with that of Prolia. After a year of treatment, bone mineral density in the spine (a measure of how strong the bones are) increased by around 5.7% in women who received Conexxence and 5.1% in those who received Prolia.
Because Conexxence is a biosimilar medicine, the studies on the effectiveness carried out with Prolia do not all need to be repeated for Conexxence.
The safety of Conexxence has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Prolia.
For the complete list of side effects and restrictions with Conexxence, see the package leaflet.
The most common side effects with Conexxence (which may affect more than 1 in 10 people) include pain in the arms or legs, and bone, joint and muscle pain. Other side effects (which may affect up to 1 in 100 people) include cellulitis (inflammation of deep skin tissue). Hypocalcaemia (low blood calcium levels), hypersensitivity (allergic reactions), osteonecrosis in the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth and loose teeth), and unusual fractures of the thigh bone may affect up to 1 in 1,000 people taking this medicine.
Conexxence must not be used in people with hypocalcaemia.
The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Conexxence has a highly similar structure, purity and biological activity to Prolia and is distributed in the body in the same way. In addition, a study has shown that Conexxence and Prolia are equivalent in terms of safety and effectiveness in women with osteoporosis who have been through the menopause.
All these data were considered sufficient to conclude that Conexxence will have the same effects as Prolia in its authorised uses. Therefore, the Agency’s view was that, as for Prolia, the benefits of Conexxence outweigh the identified risks and it can be authorised for use in the EU.
The company that markets Conexxence will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Conexxence have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Conexxence are continuously monitored. Suspected side effects reported with Conexxence are carefully evaluated and any necessary action taken to protect patients.
Conexxence received a marketing authorisation valid throughout the EU on 18 July 2025.
Product information
18/07/2025
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Conexxence
- Active substance
- denosumab
- International non-proprietary name (INN) or common name
- denosumab
- Therapeutic area (MeSH)
- Osteoporosis
- Osteoporosis, Postmenopausal
- Bone Resorption
- Anatomical therapeutic chemical (ATC) code
- M05BX04
Pharmacotherapeutic group
Drugs for treatment of bone diseasesTherapeutic indication
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures.
Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures (see section 5.1). In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures.
Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture (see section 5.1).
News on Conexxence
This page was last updated on